ストックスクリーナーアプリを入手
6.07
9.57%
0.53
アフターアワーズ：
6.00
-0.07
-1.15%
前日終値:
$5.54
開ける：
$5.61
24時間の取引高:
520.58K
Relative Volume:
0.95
時価総額：
$197.79M
収益：
$2.00M
当期純損益:
$-51.04M
株価収益率:
-3.8442
EPS:
-1.579
ネットキャッシュフロー:
$-45.65M
1週間 パフォーマンス:
+8.59%
1か月 パフォーマンス:
+16.51%
6か月 パフォーマンス:
-20.34%
1年 パフォーマンス:
+179.72%
1日の値動き範囲:
$5.55
$6.10
1週間の範囲:
$5.19
$6.10
52週間の値動き範囲:
$2.02
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.07 | 180.52M | 2.00M | -51.04M | -45.65M | -1.579 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Rodman & Renshaw | Buy |
| 2026-02-03 | 開始されました | Guggenheim | Buy |
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2025-08-11 | 開始されました | Wedbush | Outperform |
| 2025-08-07 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-24 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Risks Report: Can Sagimet Biosciences Inc deliver alpha2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
SGMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sagimet Biosciences Presents Research at Metabolic Health Summit - National Today
Sagimet Biosciences Inc. (hereinafter referred to as "Sagimet") announced that its latest research progress will be presented at the "Fueling MASH: Metabolic Drivers and Inflammatory Interactions" Keystone Symposium through poster and oral presentations. - Bitget
Sagimet Biosciences to Present Phase 2b FASCINATE 2 Trial Data for Denifanstat at Keystone Symposium on Metabolic Drivers and Inflammatory Crosstalk - Quiver Quantitative
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan
Sagimet Biosciences Inc (0O2.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Barclays Maintains Sagimet Biosciences(SGMT.US) With Hold Rating, Maintains Target Price $8 - Moomoo
SGMT SEC FilingsSagimet Biosciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - Moomoo
ETF Watch: What is Sagimet Biosciences Incs TAM Total Addressable MarketM&A Rumor & Risk Managed Investment Signals - baoquankhu1.vn
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Rodman & Renshaw - MarketBeat
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Insider Monkey
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Rallies: How does Sagimet Biosciences Inc score in quality rankingsRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
Sagimet rises after denifanstat succeeds in late stage trial - MSN
Total debt per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
EBIT per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen - marketbeat.com
Q1 Earnings Forecast for SGMT Issued By HC Wainwright - MarketBeat
Citizens reiterates Sagimet Biosciences stock rating on MASH progress - Investing.com UK
Citizens reiterates Sagimet Biosciences stock rating on MASH progress By Investing.com - Investing.com Nigeria
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target - TipRanks
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating - TipRanks
Sagimet Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sagimet Biosciences Reports 2025 Financial Results, Advances MASH and Acne Clinical Programs with Denifanstat and Resmetirom Combination 14 - Minichart
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress By Investing.com - in.investing.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright - MarketBeat
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Pipeline with Positive Phase 3 Results for Denifanstat in Acne and MASH Clinical Trials - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress - TipRanks
MASH and acne trial gains highlight Sagimet (NASDAQ: SGMT) 2025 update - Stock Titan
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall - TradingView
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
SGMT: Positive clinical progress in MASH and acne, with $113.1M cash and $51.0M net loss in 2025 - TradingView
Sagimet 10-K: Net Loss $51.0M, EPS $(1.58) - TradingView
Acne drug filing in China, new liver trial planned by Sagimet - Stock Titan
Sagimet Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):